Modern drug candidates are expected to show strong physicochemical and biopharmaceutical profiles as well as consistent delivery options before accessing preclinical development.

In order to improve candidate quality, research programs are ever more reliant upon early physicochemical properties monitoring and rational formulation design for in vivo experiments.

Over the last decade, the need for new methodologies to earlier identify more drugable molecules has clearly emerged in the pharmaceutical industry as a key element to secure return-on-investment in discovery and accelerate research-to-development transition.

Drugabilis is the first CRO specialised in pharmaceutical drugability for research. We deliver both experimental support and consulting services to our customer’s research efforts, by promoting the emergence and selection of highly-drugable compounds and suitable delivery systems, from idea to preclinical candidate.